drugset / Trial / NCT06330220

Visual Function Change in Wet Age-related Macular Degeneration Patients With Better Baseline Visual Acuity

NCT06330220

Phase 4 Completed 12 enrolled Seoul National University Hospital
NaSingle-groupOpen-labelTreatment

Summary

Although the number of wet AMD patients with the better visual acuity is increasing, the visual improvement in patients with the better vision may not be so significant after anti-vascular endothelial growth factor (VEGF) treatments because of 'ceiling effect'. The aim of current study is to investigate the improvement of visual function after aflibercept treatments using microperimetry in wet AMD patients with the better baseline visual acuity (≥20/40).

Timeline

Start
2021-02-10
Primary completion
2022-02-28
Completion
2022-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Aflibercept Protein / enzyme biologic 2 mg Intravitreal